Dechra Pharmaceuticals
↗Northwich, United Kingdom
Dechra Pharmaceuticals is a global specialist in the development, manufacture, and marketing of high-quality veterinary pharmaceuticals and related products. The company focuses on niche therapeutic areas where there is a high level of clinical need, particularly in companion animal products (CAP), equine medicine, and food-producing animal products (FAP).
Following its acquisition by the private equity firm EQT in early 2024, Dechra has transitioned from a public entity to a private one, focusing on long-term growth through innovation and strategic acquisitions. The company operates across the entire animal health value chain, with a strong presence in over 25 countries and a distribution network reaching more than 60 countries worldwide.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Veterinary Pharmaceuticals
SIZE & FINANCIALS
Employees:1001-5000
Revenue:£796M (FY 2024)
Founded:1997
Ownership:private
Status:acquired
FUNDING
Stage:Acquired
Total Raised:$4500M
Investors:EQT Partners, Abu Dhabi Investment Authority (ADIA)
STOCK
Market Cap:$5.6B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Vaccines, Monoclonal antibodies (via Invetx), Topical therapeutics
Active Trials:12
Trial Phases:Phase 1: 3 | Phase 2: 4 | Phase 3: 5
FDA Approvals:15
EMA Approvals:20
CORPORATE STRUCTURE
Parent Company:Freya Bidco Limited (EQT)
Acquired By:EQT Partners (Consortium including ADIA) (2024-01-01)
Subsidiaries:Dechra Veterinary Products, Med-Pharmex, Piedmont Animal Health, Invetx
Key Partnerships:Invetx (Strategic agreement for equine products), Vaxxinova (Divestment of poultry vaccines)
COMPETITION
Position:Leader
Competitors:Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim Animal Health, Virbac, Vetoquinol
LEADERSHIP
Key Executives:
Jesper Nordengaard - CEO
Dr. Cathy Knupp - Chief Scientific Officer
Ian MacKellar - COO
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Dechra Pharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.